A6226

AM251

>98% (HPLC), solid, cannabinoid receptor (CB1) antagonist

• Synonyme(s) : 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide
• Formule empirique (notation de Hill) : C₂₂H₂₁N₄OCl₂I
• Numéro CAS: 183232-66-8
• Poids moléculaire : 555.24
• UNSPSC Code: 12352200
• PubChem Substance ID: 24891069
• NACRES: NA.77
• MDL number: MFCD01861181
• Assay: >98% (HPLC)
• Form: solid

Propriétés

• Nom du produit: AM251, >98% (HPLC), solid
• Quality Segment: 100
• assay: >98% (HPLC)
• form: solid
• color: white
• solubility: DMSO: >10 mg/mL, H₂O: insoluble
• originator: Sanofi Aventis
• SMILES string: Cc1c(nn(-c2ccc(Cl)cc2Cl)c1-c3ccc(I)cc3)C(=O)NN4CCCCC4
• InChI: 1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
• InChI key: BUZAJRPLUGXRAB-UHFFFAOYSA-N
• Gene Information: mouse ... Cnr1(12801), Cnr2(12802) ; rat ... Cnr1(25248)

Description

Application

AM251, a CB₁ cannabinoid receptor antagonist, has been used in a study to determine its interaction with hippocampal neurons to enhance spatial memory in mice.

Biochem/physiol Actions

AM251 is a CB₁ cannabinoid receptor antagonist.

Features and Benefits

This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Salt content may vary.

Informations sur la sécurité

• hcodes: H413
• pcodes: P273 - P501
• Hazard Classifications: Aquatic Chronic 4
• Classe de stockage: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves